Stockreport

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com
PDF FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for [Read more]